MX354786B - Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. - Google Patents

Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.

Info

Publication number
MX354786B
MX354786B MX2014009595A MX2014009595A MX354786B MX 354786 B MX354786 B MX 354786B MX 2014009595 A MX2014009595 A MX 2014009595A MX 2014009595 A MX2014009595 A MX 2014009595A MX 354786 B MX354786 B MX 354786B
Authority
MX
Mexico
Prior art keywords
cancer
disorders
gastrointestinal
inflammation
treatment
Prior art date
Application number
MX2014009595A
Other languages
English (en)
Inventor
Kunwar Shailubhai
Gary S Jacob
Original Assignee
Synergy Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergy Pharmaceuticals Inc filed Critical Synergy Pharmaceuticals Inc
Publication of MX354786B publication Critical patent/MX354786B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere a novedosos péptidos del agonista de guanilato ciclasa-C y su uso en el tratamiento de enfermedades humanas que incluyen trastornos gastrointestinales, inflamación o cáncer (por ejemplo, un cáncer gastrointestinal); los péptidos se pueden administrar ya sea solos o en combinación con un inhibidor de fosfodiesterasa dependiente de GMPc; el trastorno gastrointestinal puede ser clasificado ya sea como síndrome del intestino irritable, estreñimiento, o acidez excesiva, etc.; la enfermedad gastrointestinal puede ser clasificada ya sea como enfermedad inflamatoria del intestino u otra condición del GI, incluyendo enfermedad de Crohn y colitis ulcerativa, y cáncer.
MX2014009595A 2007-06-04 2008-06-04 Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. MX354786B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93319407P 2007-06-04 2007-06-04
PCT/US2008/065824 WO2008151257A2 (en) 2007-06-04 2008-06-04 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders

Publications (1)

Publication Number Publication Date
MX354786B true MX354786B (es) 2018-03-21

Family

ID=39796867

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014009595A MX354786B (es) 2007-06-04 2008-06-04 Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
MX2009013293A MX2009013293A (es) 2007-06-04 2008-06-04 Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
MX2017012716A MX381737B (es) 2007-06-04 2008-06-04 Agonistas de guanilato ciclasa útiles en la preparación de medicamentos para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2009013293A MX2009013293A (es) 2007-06-04 2008-06-04 Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
MX2017012716A MX381737B (es) 2007-06-04 2008-06-04 Agonistas de guanilato ciclasa útiles en la preparación de medicamentos para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.

Country Status (12)

Country Link
US (11) US7879802B2 (es)
EP (3) EP2170930B3 (es)
JP (3) JP5546451B2 (es)
CN (2) CN101772513B (es)
AU (1) AU2008261102B2 (es)
CA (2) CA3089569C (es)
DK (1) DK2170930T3 (es)
EA (1) EA020466B1 (es)
ES (2) ES2559319T3 (es)
IL (2) IL202510A (es)
MX (3) MX354786B (es)
WO (1) WO2008151257A2 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233040D1 (de) 2001-03-29 2009-09-03 Synergy Pharmaceuticals Inc Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese
CA2623666C (en) 2005-09-26 2017-10-24 Lifecell Corporation Dry platelet composition
US8969514B2 (en) * 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2559840T3 (es) 2008-06-04 2016-02-16 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
CA2726917C (en) * 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
MX385591B (es) 2008-08-15 2025-03-18 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
US20120039949A1 (en) * 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
EP2373296B1 (en) * 2008-12-03 2016-08-03 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2010099234A1 (en) * 2009-02-24 2010-09-02 Thomas Jefferson University Use of guanylyl cyclase c agonists to suppress appetite
WO2011017502A2 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
RU2012109415A (ru) 2009-08-13 2013-09-20 Айронвуд Фармасьютикалз, Инк. Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы
CA2774032C (en) 2009-10-23 2019-03-26 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods
US8507447B2 (en) 2009-11-09 2013-08-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
RU2012128509A (ru) 2009-12-07 2014-01-20 Айронвуд Фармасьютикалз, Инк. Способы лечения заболеваний желудочно-кишечного тракта
CN102869677B (zh) * 2010-02-17 2015-07-08 硬木药品公司 胃肠病症的治疗
CA2808091C (en) 2010-08-11 2019-05-21 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012037380A2 (en) * 2010-09-15 2012-03-22 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EA201391254A1 (ru) * 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. Способ получения агонистов гуанилатциклазы c
CA2835624A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US20160213739A1 (en) * 2011-05-11 2016-07-28 Ironwood Pharmaceuticals, Inc Treatments for disorders using guanylate cyclase c agonists
US9303066B2 (en) * 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012161921A1 (en) * 2011-05-23 2012-11-29 Thomas Jefferson University Intestinal hyperpermeability and prevention of systemic disease
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2013013338A1 (zh) * 2011-07-25 2013-01-31 北京生命科学研究所 以gc-c信号通路为靶点的物质在中脑多巴胺神经元疾病诊断和治疗方面的用途
JP6312592B2 (ja) 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化器疾患の治療
US20130123264A1 (en) * 2011-10-17 2013-05-16 Darren D. Browning Compositions and methods for treatment of inflammatory bowel disorders and intestinal cancers
EA034689B1 (ru) 2012-04-27 2020-03-06 Милленниум Фармасьютикалз, Инк. Молекула антитела к gcc и ее применение для тестирования на чувствительность к gcc-нацеленной терапии
JP6499591B2 (ja) * 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN104211777A (zh) * 2013-05-30 2014-12-17 深圳翰宇药业股份有限公司 一种皮卡那肽的制备方法
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
EP3492106B1 (en) 2013-08-09 2021-02-17 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US20160367622A1 (en) * 2013-10-10 2016-12-22 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
CA2926691A1 (en) * 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
AU2015301596B2 (en) * 2014-08-13 2020-04-16 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US10188645B2 (en) 2015-08-26 2019-01-29 Ian Cain Smith Methods and compositions for ameliorating symptoms of termination of opioid pain therapy
EP3377113A4 (en) * 2015-11-18 2019-06-19 Synergy Pharmaceuticals, Inc. COMPOSITIONS AND METHODS OF TREATMENT AND DETECTION OF CANCER
JP2019506383A (ja) * 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド 潰瘍性大腸炎を治療するための製剤および方法
TWI656879B (zh) 2016-01-26 2019-04-21 財團法人工業技術研究院 用於治療或減緩自體免疫疾病及／或其併發症及／或腎炎的醫藥組成物以及其有效成分之用途
KR102863391B1 (ko) 2016-02-04 2025-09-22 앨러스틴 스킨케어, 인크. 침습 및 비침습 시술적 피부 관리를 위한 조성물 및 방법
CN107349417A (zh) * 2017-04-01 2017-11-17 南阳市中心医院 一种治疗食管鳞癌的ecm复合物以及其在制备治疗食管鳞癌的药物中的用途
US10493011B2 (en) 2017-08-03 2019-12-03 ALASTIN Skincare, Inc. Peptide compositions and methods for ameliorating skin laxity and body contour
US11103455B2 (en) 2018-08-02 2021-08-31 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN114144224B (zh) 2019-03-26 2024-08-09 保科特纳洛克斯恩公司 药物合成物输送器械和方法
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
BR112021024938A2 (pt) 2019-06-12 2022-01-25 Novartis Ag Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
WO2021231928A1 (en) * 2020-05-15 2021-11-18 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an fgfr4 inhibitor
WO2021252951A1 (en) 2020-06-12 2021-12-16 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
WO2025226772A1 (en) * 2024-04-23 2025-10-30 Cindome Pharma, Inc. Methods for treating gastroesophagael symptoms in cystic fibrosis patients

Family Cites Families (965)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US488064A (en) 1892-12-13 Magnetic separator
US2809194A (en) 1957-10-08 Thiadiazine type natriuretic agents
US3108097A (en) 1963-10-22 Ehnojs
DE1116676B (de) 1955-03-14 1961-11-09 Thomae Gmbh Dr K Verfahren zur Herstellung von Pyrimido [5, 4-d] pyrimidinen
FR1217929A (fr) 1958-03-03 1960-05-06 Ciba Geigy Procédé de préparation du 1,1-dioxyde de la 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine et de ses sels
BE578515A (es) 1958-05-07
DE1302648B (es) 1960-09-27
NL281975A (es) 1961-08-12
GB1051218A (es) 1963-03-09
NL127065C (es) 1964-04-22
NL137318C (es) 1964-06-09
GB1078852A (en) 1964-09-30 1967-08-09 Ici Ltd Alkanolamine derivatives
US3466325A (en) 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3636039A (en) 1970-02-24 1972-01-18 Hoffmann La Roche Substituted benzylimidazolidinones
GB1361441A (en) 1970-05-13 1974-07-24 Sandoz Ltd Benzonaphthyridine derivatives
US4059622A (en) 1970-05-27 1977-11-22 Imperial Chemical Industries Limited Alkanolamine derivatives
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
DE2117571C3 (de) 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
BE794964A (fr) 1972-02-04 1973-08-02 Bristol Myers Co Nouveaux agents hypotenseurs et procede pour les preparer
JPS5229318B2 (es) 1972-03-30 1977-08-01
DE2305339C3 (de) 1973-02-03 1980-05-08 Dr. Karl Thomae Gmbh, 7950 Biberach Imidazo [4,5-b] pyridine, ihre Herstellung und ihre Verwendung als Cardiötonica
US4062950A (en) 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
AR205004A1 (es) 1973-10-30 1976-03-31 Ishikawa M Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona
US4016166A (en) 1973-12-14 1977-04-05 Hisamitsu Pharmaceutical Co., Inc. 1-Nitrophenylquinazoline-2,4(1H,3H)-diones
AT334385B (de) 1973-12-20 1976-01-10 Chemie Linz Ag Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen
DE2462367A1 (de) 1974-01-22 1976-11-11 Wuelfing J A Fa 7-(oxoalkyl)-1,3-dialkylxanthine enthaltende arzneimittelzubereitungen
DE2413935A1 (de) 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
DE2521113A1 (de) 1974-05-15 1976-03-18 Maggioni & C Spa Cycloaliphatische derivate von 3.3-diphenylpropylamin
US3914250A (en) 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US4072746A (en) 1975-10-14 1978-02-07 Sterling Drug Inc. 3-Amino-5-(pyridinyl)-2(1H)-pyridinones
US4046889A (en) 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
JPS608117B2 (ja) 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
DE2719912C3 (de) 1977-05-04 1979-12-06 Bayer Ag, 5090 Leverkusen Verfahren zur Isolierung von 0- |4,6-Dideoxy-4- [JJl S-O,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2cyclohexen-1-yl] -amino] - a -D-glucopyranosyl} -(I Pfeil nach rechts 4)-0- a D-glucopyranosyl-(l Pfeil nach rechts 4)-D-glucopyranose aus Kulturbrühen
IE46852B1 (en) 1977-06-10 1983-10-05 Otsuka Pharma Co Ltd Novel carbostyril derivatives
DE2727481A1 (de) 1977-06-18 1979-01-11 Basf Ag Dihydropyridazone und dihydropyridazone enthaltende therapeutische mittel
US4466972A (en) 1977-06-20 1984-08-21 Sandoz Ltd. Benzoxadiazoles and benzothiadiazoles, their preparation and pharmaceutical compositions containing them
NL7807507A (nl) 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
CA1114379A (en) 1977-11-03 1981-12-15 Pfizer Corporation Piperidino-phthalazines
JPS5953920B2 (ja) 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
CA1121290A (en) 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
JPS54148788A (en) 1978-05-15 1979-11-21 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative and its preparation
JPS5527105A (en) 1978-08-11 1980-02-27 Dai Ichi Seiyaku Co Ltd Imidazothienopyrimidinones compound
US4316906A (en) 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
DE2837161A1 (de) 1978-08-25 1980-03-06 Thomae Gmbh Dr K Neue benzimidazole und deren verwendung
JPS5535019A (en) 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2845220A1 (de) 1978-10-17 1980-04-30 Yoshitomi Pharmaceutical Pyridazinon-derivate, ihre salze mit saeuren, verfahren zu ihrer herstellung und ihre verwendung bei der behandlung von thrombosen und hypertonie
US4168267A (en) 1978-10-23 1979-09-18 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl prolines
DE2847693A1 (de) 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
NZ193935A (en) 1979-06-18 1985-05-31 Richardson Merrell Inc 4-aroyl-imidazol-2-one derivatives;pharmaceutical compositions
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
GB2063249A (en) 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
IL61501A (en) 1979-11-26 1984-06-29 Sterling Drug Inc 5-(pyridinyl)-2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ES505959A0 (es) 1980-10-09 1982-09-01 Hoechst Ag Procedimiento para la preparacion de un inactivador de alfa-amilasa
JPS5777676A (en) 1980-10-31 1982-05-15 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US4337201A (en) 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
EP0056194B1 (en) 1981-01-05 1984-09-12 Takeda Chemical Industries, Ltd. N-substituted pseudo-aminosugars, their production and use
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3107100A1 (de) 1981-02-20 1982-09-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US4405628A (en) 1981-03-05 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Pyridylimidazolones and method of use
EP0060668B1 (en) 1981-03-12 1985-10-09 Beecham Group Plc N-carboxyalkyl dipeptide derivatives and pharmaceutical compositions thereof
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4452813A (en) 1981-05-22 1984-06-05 Taiho Pharmaceutical Company Limited Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative
US4432971A (en) 1981-08-03 1984-02-21 E. R. Squibb & Sons, Inc. Phosphonamidate compounds
CY1403A (en) 1981-08-11 1987-12-18 Ciba Geigy Ag Benzazepin-2-ones
HU190412B (en) 1981-09-17 1986-09-29 Warner-Lambert Co,Us Process for producing substituted 4,5-dihiydro-6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones and 6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
EP0080822A1 (en) 1981-11-27 1983-06-08 Beecham Group Plc Anti-hypertensive prolinol-based peptides
EP0096517A3 (en) 1982-06-05 1985-04-03 Smith Kline & French Laboratories Limited Aryl pyrazinones
US4452790A (en) 1982-06-23 1984-06-05 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4473575A (en) 1982-07-19 1984-09-25 Ciba-Geigy Corporation 3-Amino-(1)-benzazepin-2-one-1-alkanoic acids
DE3241102A1 (de) 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
US4490371A (en) 1983-02-16 1984-12-25 Syntex (U.S.A.) Inc. N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4503030A (en) 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
GB8400863D0 (en) 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
FI844289A7 (fi) 1984-01-21 1985-07-22 Hoechst Ag Uusia polypeptidejä, joilla on -amylaasi-estävä vaikutus, niiden käyttö ja farmaseuttiset valmistee
NL8400924A (nl) 1984-03-23 1985-10-16 Philips Nv Gelijkstroom-wisselstroomomzetter voor het ontsteken en voeden van een gas-en/of dampontladingsbuis.
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
WO1985005029A1 (en) 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
DK159431C (da) 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
PL144822B1 (en) 1984-05-12 1988-07-30 Boehringer Mannheim Gmbh Method of obtaining novel pyrolobenzimidazoles
CA1248099A (en) 1984-05-14 1989-01-03 David W. Robertson Indoline and 2-indolinone derivatives
DE3424685A1 (de) 1984-07-05 1986-02-06 Beiersdorf Ag, 2000 Hamburg Neue substituierte phenylpiperazinyl-propanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
US4634765A (en) 1984-12-18 1987-01-06 Merrell Dow Pharmaceuticals Inc. Homodisaccharide hypoglycemic agents
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
JPS61218589A (ja) 1985-03-26 1986-09-29 Eisai Co Ltd ５―（６―イミダゾ〔１，２―ａ〕ピリジニル）ピリジン誘導体
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
PT83530B (pt) 1985-10-17 1989-05-31 Smith Kline French Lab Processo de preparacao de derivados da piridona, em especial derivados fenilicos
IL77186A0 (en) 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US5036048A (en) 1986-03-07 1991-07-30 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
WO1987006576A1 (en) 1986-04-29 1987-11-05 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
DE3779374D1 (en) 1986-08-28 1992-07-02 Sandoz Ag Xanthinderivate.
NZ222843A (en) 1986-12-22 1989-10-27 Ortho Pharma Corp Benzoxazinyl- and benzothiazinyl-tetrahydropyridazinones and intermediates, and medicaments
GB8630702D0 (en) 1986-12-23 1987-02-04 Wellcome Found Quinoline compound
WO1988005306A1 (en) 1987-01-23 1988-07-28 The General Hospital Corporation Atriopeptins, guanylate cyclase activators, and phosphodiesterase inhibitors as treatment for glaucoma, hydrocephalus and cerebral edema (cranial fluid volume dysfunction)
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
IT1217123B (it) 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
US5041152A (en) 1987-03-26 1991-08-20 Kabushiki Kaisha Toshiba Apparatus for bending tubular glass
AU614965B2 (en) 1987-06-06 1991-09-19 Merck Patent Gesellschaft Mit Beschrankter Haftung Thiadiazinones
IL87149A (en) 1987-07-20 1994-05-30 Merck & Co Inc 6-Piperazinyl derivatives of purine and its 3- and 9-deaza isosteres, their preparation and pharmaceutical compositions containing them
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
EP0842925A1 (en) 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5192772A (en) 1987-12-09 1993-03-09 Nippon Shinyaku Co. Ltd. Therapeutic agents
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
ATE90570T1 (de) 1988-01-29 1993-07-15 Sumitomo Pharma Verbesserte formulierungen mit kontrollierter abgabe.
JP2717687B2 (ja) 1988-02-13 1998-02-18 日本曹達株式会社 ピリダジノン誘導体及びその製造方法
US5142096A (en) 1988-03-31 1992-08-25 Kyowa Hakko Kogyo Co., Ltd. 2,4-dihydroxy-3,5,6-trimethylbenzoic acid compounds
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
EP0344383A1 (en) 1988-06-02 1989-12-06 Merrell Dow Pharmaceuticals Inc. Novel alpha-Glucosidase inhibitors
JP2792862B2 (ja) 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5106834A (en) 1988-12-27 1992-04-21 G. D. Searle & Co. Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents
US4916129A (en) 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
CA2065364A1 (en) 1989-04-17 1990-10-18 Hermann Amschler Arylpyridazines, their manufacture, use and medicaments containing them
CA2016710A1 (en) 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
US5157026A (en) 1989-05-30 1992-10-20 Merck & Co., Inc. Oxo-purines as angiotensin II antagonists
US5102880A (en) 1989-05-30 1992-04-07 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
IL94390A (en) 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
US5185351A (en) 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
DE69033469T2 (de) 1989-06-14 2000-09-07 Smithkline Beecham Corp., Philadelphia Imidazoalkensäure
CA2018443A1 (en) 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids
JP2568315B2 (ja) 1989-06-30 1997-01-08 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー 縮合環アリール置換イミダゾール
KR0163595B1 (ko) 1989-06-30 1998-12-01 미리암디, 메코너헤이 치환된 이미다졸
US5164407A (en) 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
CA2020073A1 (en) 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
NZ234186A (en) 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
EP0412594B1 (en) 1989-07-28 1996-01-03 Merck & Co. Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
CH679207A5 (es) 1989-07-28 1992-01-15 Debiopharm Sa
EP0411507B1 (en) 1989-08-02 1994-10-26 Takeda Chemical Industries, Ltd. Pyrazole derivatives, their production and use
IE902909A1 (en) 1989-08-11 1991-02-27 Ici Plc Nitrogen compounds
JP2862576B2 (ja) 1989-08-14 1999-03-03 日産自動車株式会社 カチオン電着塗料組成物
US5100897A (en) 1989-08-28 1992-03-31 Merck & Co., Inc. Substituted pyrimidinones as angiotensin ii antagonists
EP0415886A3 (en) 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
EP0424317A3 (en) 1989-10-19 1991-09-25 Ciba-Geigy Ag Pyrimidines
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
CA2027937A1 (en) 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
IL96019A0 (en) 1989-10-31 1991-07-18 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
US4943573A (en) 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
CA2028925A1 (en) 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
WO1991007501A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Enzymatic resolution of endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents
US5391571A (en) 1989-11-15 1995-02-21 American Home Products Corporation Cholesterol ester hydrolase inhibitors
PT95899A (pt) 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
IE903911A1 (en) 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
US5073566A (en) 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
EP0430709A3 (en) 1989-12-01 1992-02-12 Glaxo Group Limited Benzthiophen derivatives
GB8927277D0 (en) 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
EP0430300A3 (en) 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
US5104891A (en) 1989-12-11 1992-04-14 G. D. Searle & Co. Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension
EP0433983B1 (en) 1989-12-20 1998-03-04 Texas Instruments Incorporated Copper etch process using halides
EP0434038A1 (en) 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
GB8929208D0 (en) 1989-12-27 1990-02-28 Almirall Lab New xanthine derivatives
EP0435827A3 (en) 1989-12-28 1991-11-13 Ciba-Geigy Ag Diaza compounds
CA2032289A1 (en) 1989-12-29 1991-06-30 Joseph A. Finkelstein Substituted 5-(alkyl) carboxamide imidazoles
CA2075639A1 (en) 1990-02-13 1991-08-14 William J. Greenlee Triazole angiotensin ii antagonists incorporating a substituted benzyl element
EP0515535A4 (en) 1990-02-13 1996-01-17 Merck & Co Inc Angiotensin ii antagonists incorporating a substituted benzyl element
ATE169915T1 (de) 1990-02-15 1998-09-15 Takeda Chemical Industries Ltd Pyrimidindionderivate, deren herstellung und verwendung
ATE134624T1 (de) 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
CA2036618C (en) 1990-02-22 2002-10-29 Akira Morimoto Fused thiophene derivatives, their production and use
US4963561A (en) 1990-02-28 1990-10-16 Sterling Drug Inc. Imidazopyridines, their preparation and use
DE4006693A1 (de) 1990-03-01 1991-09-05 Schering Ag Neue benzimidazolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US5081122A (en) 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
CA2037630C (en) 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
US4973587A (en) 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5013837A (en) 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
GB9005354D0 (en) 1990-03-09 1990-05-02 Glaxo Group Ltd Chemical compounds
US5287273A (en) 1990-03-15 1994-02-15 Mount Sinai School Of Medicine Functional organ images
FR2659655B1 (fr) 1990-03-19 1992-07-24 Union Pharma Scient Appl Nouveaux derives d'oxypyrazole antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2681067B1 (fr) 1991-09-10 1993-12-17 Elf Sanofi Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
US5140037A (en) 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
TW201738B (es) 1990-03-20 1993-03-11 Sanofi Co
US5155126A (en) 1990-03-20 1992-10-13 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with pyrazole, pyrrole and triazole angiotensin-II receptor antagonists
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5137906A (en) 1990-03-20 1992-08-11 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with benzimidazole angiotensin-II receptor antagonists
US5173494A (en) 1990-03-20 1992-12-22 E. I. Du Pont De Nemours And Company Specific inhibition of angiotensin-II binding to angiotensin-II receptor subtype-2
US5223516A (en) 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
JPH05505609A (ja) 1990-03-30 1993-08-19 メルク・エンド・カムパニー・インコーポレーテツド 置換ピリミジン、ピリミジノンおよびピリドリミジン
CA2079343A1 (en) 1990-03-30 1991-10-01 Eric E. Allen Substituted pyrazoles, isoxazoles and isothiazoles
DE4010797A1 (de) 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
WO1991015206A1 (en) 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
US5175003A (en) 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
JPH05507469A (ja) 1990-04-13 1993-10-28 スミスクライン・ビーチャム・コーポレイション 置換ベンズイミダゾール
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
EP0453210A3 (en) 1990-04-19 1993-01-13 Imperial Chemical Industries Plc Pyridine derivatives
HU208124B (en) 1990-04-25 1993-08-30 Nissan Chemical Ind Ltd Process for producing pyridazinone derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
US5703110A (en) 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5642868A (en) 1990-05-02 1997-07-01 The United States Of America As Represented By The Secretary Of The Navy Ceramic material
US5098920A (en) 1990-05-04 1992-03-24 G. D. Searle & Co. 1h-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders
IL98087A (en) 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
GB9010394D0 (en) 1990-05-09 1990-06-27 Ici Plc Heterocyclic compounds
MY105344A (en) 1990-05-16 1994-09-30 Byk Gulden Lomberg Chemische Fabrik New sulphonyl compounds
US5045540A (en) 1990-05-25 1991-09-03 Warner-Lambert Co. Amino acid derivatives with angiotensin II antagonist properties
WO1991018888A1 (en) 1990-05-25 1991-12-12 G.D. Searle & Co. N-substituted-1,2,4-triazolone compounds for treatment of cardiovascular disorders
JPH04235974A (ja) 1990-06-08 1992-08-25 Roussel Uclaf 新規なイミダゾール誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
US5504078A (en) 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
WO1991019715A1 (en) 1990-06-15 1991-12-26 G.D. Searle & Co. 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
CN1034934C (zh) 1990-06-19 1997-05-21 明治制果株式会社 血管紧张素ii拮抗性吡啶衍生物的制备方法
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
EP0533840B1 (en) 1990-06-22 1996-12-11 E.I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
NZ238688A (en) 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof
IE912114A1 (en) 1990-07-02 1992-01-15 Union Pharma Scient Appl Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present
US5053329A (en) 1990-07-05 1991-10-01 Merck & Co., Inc. Process for preparation of novel angiotensin II antagonists
IL98319A (en) 1990-07-05 1997-04-15 Roussel Uclaf Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
IL98764A0 (en) 1990-07-10 1992-07-15 Smithkline Beecham Corp Oxamides
US5137902A (en) 1990-07-13 1992-08-11 E. I. Du Pont De Nemours And Company 4-alkylimidazole derivatives and anti-hypertensive use thereof
CA2044806A1 (en) 1990-07-18 1992-01-19 Roland Jaunin Purine derivatives
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US5132216A (en) 1990-07-19 1992-07-21 Merck & Co., Inc. Microbial transformation process for antihypertensive products
CA2047029A1 (en) 1990-07-19 1992-01-20 Shieh-Shung T. Chen Microbial transformation process for antihypertensive products
US5057522A (en) 1990-07-19 1991-10-15 Merck & Co., Inc. Anti-hypersensitive N2-tetrazole-β-glucuronide analog
DE4023215A1 (de) 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
RU1836357C (ru) 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами
NZ239161A (en) 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
US5124455A (en) 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
GB9017482D0 (en) 1990-08-09 1990-09-26 Ici Plc Manufacturing process
GB9017480D0 (en) 1990-08-09 1990-09-26 Ici Plc Chemical process
GB9017479D0 (en) 1990-08-09 1990-09-26 Ici Plc Process
WO1992002257A2 (en) 1990-08-10 1992-02-20 G.D. Searle & Co. Renal-selective angiotensin ii antagonists for treatment of hypertension
EP0470543A1 (de) 1990-08-10 1992-02-12 Dr. Karl Thomae GmbH Heterocyclische Imidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zur ihrer Herstellung
US5066586A (en) 1990-08-20 1991-11-19 Merck & Co., Inc. Process for preparation of novel angiotensin II antagonists
US5089626A (en) 1990-08-23 1992-02-18 Merck & Co., Inc. Process for preparing an angiotensin II antagonist
US5217985A (en) 1990-08-28 1993-06-08 G. D. Searle & Co. Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension
AU8405691A (en) 1990-09-04 1992-03-30 Yamanouchi Pharmaceutical Co., Ltd. Novel tetrahydrobenzazole derivative
IL99372A0 (en) 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
EP0549712A1 (en) 1990-09-11 1993-07-07 Mectra Labs, Inc. Disposable lavage
US5140036A (en) 1990-09-19 1992-08-18 G. D. Searle & Co. 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5210092A (en) 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
US5217877A (en) 1990-09-28 1993-06-08 Bristol-Myers Squibb Company Process for the preparation of α-glucosidase inhibitor, pradimicin Q
US5242939A (en) 1990-09-28 1993-09-07 Warner-Lambert Company Anilide derivatives with angiotensin ii antagonist properties
US5091418A (en) 1990-09-28 1992-02-25 Bristol-Myers Squibb Company Novel alpha-glucosidase inhibitor, pradimicin Q
US5126342A (en) 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
EP0481614A1 (en) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
CA2053148A1 (en) 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
AU8722991A (en) 1990-10-16 1992-05-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Arylpyridazinones
CA2053340C (en) 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5130333A (en) 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
WO1992007852A1 (en) 1990-10-25 1992-05-14 G.D. Searle & Co. Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders
AU636066B2 (en) 1990-10-30 1993-04-08 Takeda Chemical Industries Ltd. Thienoimidazole derivatives, their production and use
US5087634A (en) 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
PH31175A (en) 1990-10-31 1998-03-20 Squibb & Sons Inc Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives.
DE4036645A1 (de) 1990-11-16 1992-05-21 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, deren enthaltende mittel und deren verwendung
GB9026006D0 (en) 1990-11-29 1991-01-16 Glaxo Group Ltd Chemical compounds
JPH06503562A (ja) 1990-11-30 1994-04-21 スミスクライン・ビーチャム・コーポレイション 置換５−アリールイミダゾール
US5049565A (en) 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
CA2057089A1 (en) 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
GB9027197D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027055D0 (en) 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
AU657498B2 (en) 1990-12-14 1995-03-16 Novartis Ag Biphenylyl compounds
GB9027201D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027209D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027208D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027210D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
KR100222252B1 (ko) 1990-12-14 1999-10-01 스튜어트 알. 수터 안지오텐신 ii 수용체 차단 조성물
GB9027211D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027200D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027199D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027198D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027212D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
JPH04234389A (ja) 1990-12-28 1992-08-24 Sapporo Breweries Ltd ナフチリジン誘導体及びそれを有効成分とする抗潰瘍剤
US5141931A (en) 1991-01-03 1992-08-25 Sterling Winthrop Inc. 5-Quinolinylpyridinones, cardiotonic compositions and methods
CA2058198A1 (en) 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
IE914572A1 (en) 1991-01-17 1992-07-29 Zeneca Ltd Chemical process
IE914573A1 (en) 1991-01-17 1992-07-29 Ici Plc Boron compounds
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
US5124335A (en) 1991-01-30 1992-06-23 Merck & Co., Inc. Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists
US5087702A (en) 1991-01-30 1992-02-11 Merck & Co., Inc. Microbial transformation process for producing an antihypertensive product
US5290780A (en) 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5153347A (en) 1991-01-31 1992-10-06 E. R. Squibb & Sons, Inc. Phosphonate, phosphinate derivatives useful as antihypertensive agents
AT395853B (de) 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
EP0498361A3 (en) 1991-02-06 1992-09-02 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
JP3531944B2 (ja) 1991-02-07 2004-05-31 アベンティス・ファーマ・ソシエテ・アノニム 新規のベンジル基で置換された窒素系二環式誘導体及びその製造方法
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
GB9102727D0 (en) 1991-02-08 1991-03-27 Ici Plc Pharmaceutical agent
IE920175A1 (en) 1991-02-11 1992-08-12 Zeneca Ltd Nitrogen heterocycles
GB9102803D0 (en) 1991-02-11 1991-03-27 Ici Plc Pyridine compounds
GB9102804D0 (en) 1991-02-11 1991-03-27 Ici Plc Heterocyclic derivatives
IL100917A0 (en) 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
FR2672892B1 (fr) 1991-02-20 1994-01-14 Synthelabo Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.
IE920540A1 (en) 1991-02-21 1992-08-26 Sankyo Co 1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use
US5104877A (en) 1991-02-25 1992-04-14 Abbott Laboratories Psoriasis treatment
CA2061159A1 (en) 1991-02-26 1992-08-27 Michael A. Poss Imidazole and benzimidazole derivatives
US5187271A (en) 1991-02-28 1993-02-16 G. D. Searle & Co. N-substituted (α-imidazolyl-toluyl) pyrrole compounds for treatment of circulatory disorders
FR2673427B1 (fr) 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
EP0503838A3 (en) 1991-03-08 1992-10-07 Merck & Co. Inc. Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
US5191086A (en) 1991-03-19 1993-03-02 E.R. Squibb & Sons, Inc. Imidazole and benzimidazole derivatives
EP0505098A1 (en) 1991-03-19 1992-09-23 Merck & Co. Inc. Imidazole derivatives bearing acidic functional groups as angiotensin II antagonists
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5187179A (en) 1991-03-22 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
US5128327A (en) 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
WO1992016552A1 (en) 1991-03-25 1992-10-01 Glaxo Group Limited 1-imidazolgemethyl benzofuran derivatives as inhibitors of angiotensin ii activity
IE73235B1 (en) 1991-03-25 1997-05-21 Akzo Nv 4-aryl-thiazole or imidazole derivatives
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
DE4110019C2 (de) 1991-03-27 2000-04-13 Merck Patent Gmbh Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
FR2674849B1 (fr) 1991-04-02 1994-12-23 Logeais Labor Jacques Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
US5164403A (en) 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
US5157040A (en) 1991-04-05 1992-10-20 Merck & Co., Inc. Substituted quinolines as angiotensin ii antagonists
US5151435A (en) 1991-04-08 1992-09-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating an indole or dihydroindole
US5155117A (en) 1991-04-12 1992-10-13 G. D. Searle & Co. 1-arylheteroarylalkyl substituted-1h-1,2,4-triazole compounds for treatment of circulatory disorders
TW274551B (es) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
US5190942A (en) 1991-04-22 1993-03-02 E. R. Squibb & Sons, Inc. Benzoxazole and related heterocyclic substituted imidazole and benzimidazole derivatives
US5252574A (en) 1991-04-26 1993-10-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
EP0581805A1 (de) 1991-04-26 1994-02-09 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridazine
SK117793A3 (en) 1991-04-29 1994-05-11 Merck & Co Inc Optimized tablet formulation
GB9109246D0 (en) 1991-04-30 1991-06-19 Ici Plc Nitrogen derivatives
US5191084A (en) 1991-05-01 1993-03-02 American Home Products Corporation Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents
US5162325A (en) 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
US5198438A (en) 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
JPH05112533A (ja) 1991-05-08 1993-05-07 Upjohn Co:The イミダゾベンゾキノン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
US5223501A (en) 1991-05-10 1993-06-29 Merck & Co., Inc. Substituted pyrimidinones bearing acidic functional groups as angiotensin ii antagonists
US5238942A (en) 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
EP0586513A1 (en) 1991-05-10 1994-03-16 Merck & Co. Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
GB9110532D0 (en) 1991-05-15 1991-07-03 Smithkline Beecham Corp Chemical compounds
NZ242724A (en) 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
JPH06211845A (ja) 1991-05-16 1994-08-02 Glaxo Group Ltd ベンゾフラン誘導体
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
WO1992020679A1 (en) 1991-05-16 1992-11-26 Glaxo Group Limited Benzofuran derivatives
GB9110625D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
WO1992020661A1 (en) 1991-05-22 1992-11-26 Merck & Co., Inc. N, n-diacylpiperazines
FR2676734B1 (fr) 1991-05-23 1995-05-19 Roussel Uclaf Nouveaux derives de la pyrimidine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
IL101860A0 (en) 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
US5175164A (en) 1991-06-05 1992-12-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted indole or dihydroindole
JPH05213884A (ja) 1991-06-14 1993-08-24 Upjohn Co:The 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
US5210211A (en) 1991-06-21 1993-05-11 Warner-Lambert Company 4-(1h-pyrrol-1-yl) imidazoles with angiotension ii antagonist activity
FR2677984B1 (fr) 1991-06-21 1994-02-25 Elf Sanofi Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
GB9113626D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic compounds
GB9113628D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic derivatives
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
IL102365A0 (en) 1991-07-03 1993-01-14 Merck & Co Inc Substituted triazolinones,their preparation and pharmaceutical compositions containing them
FR2678618B1 (fr) 1991-07-05 1993-11-05 Upsa Laboratoires Nouveaux derives de triazolo pyrimidine antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
DE4123341A1 (de) 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5177097A (en) 1991-07-24 1993-01-05 E. R. Squibb & Sons, Inc. Acyl amidine and acyl, guanidine substituted biphenyl derivatives
GB9116039D0 (en) 1991-07-25 1991-09-11 Ucb Sa Substituted cyclopropylamino-1,3,5-triazines
AU2338992A (en) 1991-07-26 1993-03-02 G.D. Searle & Co. Carbonate-substituted imidazo(4,5-d) pyridazine compounds for treatment of cardiovascular disorders
IT1250749B (it) 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
WO1993003040A1 (fr) 1991-08-05 1993-02-18 Taisho Pharmaceutical Co., Ltd. Derive de thienopyrimidin-4-one
US5225401A (en) 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
US5246944A (en) 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
DK0528762T3 (da) 1991-08-15 1997-08-25 Ciba Geigy Ag N-acyl-N-heterocyclyl- eller naphthylalkyl-aminosyrer som angiotensin II antagonister
JPH06510763A (ja) 1991-08-19 1994-12-01 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー アンジオテンシン２受容体遮断イミダゾリノン誘導体
CZ36294A3 (en) 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
DE4129340A1 (de) 1991-09-04 1993-03-11 Merck Patent Gmbh 1,2-dihydro-2-oxopyridine
WO1993005025A1 (en) 1991-09-06 1993-03-18 Glaxo Group Limited C-linked pyrazole derivatives
CA2077419C (en) 1991-09-10 1998-08-25 Yasushi Honma Imidazopyridine derivatives and process for preparation thereof
ATE146474T1 (de) 1991-09-10 1997-01-15 Tanabe Seiyaku Co Imidazoindolizinderivate mit angiotensin-ii hemmwirkung
TW300219B (es) 1991-09-14 1997-03-11 Hoechst Ag
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
US5202322A (en) 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
CA2078759C (en) 1991-09-27 2003-09-16 Alan M. Warshawsky Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
EP0534363B1 (en) 1991-09-27 1997-07-09 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
AU657793B2 (en) 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
DE4132633A1 (de) 1991-10-01 1993-04-08 Bayer Ag Cyclisch substituierte imidazolyl-propensaeurederivate
DE4132632A1 (de) 1991-10-01 1993-04-08 Bayer Ag Substituierte imidazolyl-propensaeurederivate
DE4132631A1 (de) 1991-10-01 1993-04-08 Bayer Ag Imidazolyl-propensaeurederivate
AT398202B (de) 1991-10-04 1994-10-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
CA2079982A1 (en) 1991-10-07 1993-04-08 Stephen E. De Laszlo Substituted pyrazino (2,3-d)-pyrimidinones as angiotensin ii antagonists
US5187159A (en) 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
DK0612321T3 (da) 1991-10-09 1999-12-13 Syntex Inc Pyridopyridazinon- og pyridazinthionforbindelser med PDE IV inhiberende aktivitet
GB9121463D0 (en) 1991-10-10 1991-11-27 Smithkline Beecham Corp Medicament
GB9121727D0 (en) 1991-10-14 1991-11-27 Ici Plc Heterocyclic compounds
US5149699A (en) 1991-10-24 1992-09-22 American Home Products Corporation Substituted pyridopyrimidines useful as antgiotensin II antagonists
US5336677A (en) 1991-10-24 1994-08-09 American Home Products Corporation Substituted aminopyrimidines as antihypertensives
TW226375B (es) 1991-10-24 1994-07-11 American Home Prod
JPH06107661A (ja) 1991-10-24 1994-04-19 Upjohn Co:The イミダゾール誘導体およびこれを有効成分とする医薬組成物
US5234936A (en) 1991-10-24 1993-08-10 American Home Products Corporation Pyrimidocycloalkanes as a ii antagonists
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
FR2683819B1 (fr) 1991-10-28 1994-02-11 Synthelabo Derives de quinoleine, leur procede de preparation et leur application en therapeutique.
JP3221894B2 (ja) 1991-10-31 2001-10-22 ダウ・コ−ニング・コ−ポレ−ション 分岐オルガノポリシロキサンの製造方法
US5252753A (en) 1991-11-01 1993-10-12 Ortho Pharmaceutical Corporation Process for the preparation of certain substituted biphenyl tetrazoles and compounds thereof
DE4221583A1 (de) 1991-11-12 1993-05-13 Bayer Ag Substituierte biphenylpyridone
US5182288A (en) 1991-11-13 1993-01-26 Ortho Pharmaceutical Corporation Substituted n-biphenylyl lactams
EP0543263A3 (en) 1991-11-16 1993-08-25 Dr. Karl Thomae Gmbh Benziimidazoles, pharmaceuticals containing them and process for their preparation
US5130439A (en) 1991-11-18 1992-07-14 Lo Young S Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists
AU3237193A (en) 1991-12-11 1993-07-19 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5212177A (en) 1991-12-16 1993-05-18 E. R. Squibb & Sons, Inc. Indole and benzimidazole-substituted dihydropyrimidine derivatives
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
SG50624A1 (en) 1991-12-30 1998-07-20 Neurex Corp Methods of producing analgesia and enhancing opiate analgesia
WO1993015045A1 (en) 1992-01-29 1993-08-05 Smithkline Beecham Corporation N-(3-phenylpropyl)oxamic acid, oxamate, and oxamide derivatives
AU3588693A (en) 1992-01-29 1993-09-01 Smithkline Beecham Corporation N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as TNF and PDE IV inhibitors
GB9204808D0 (en) 1992-03-04 1992-04-15 Rhone Poulenc Rorer Ltd Novel compositions of matter
US5208234A (en) 1992-03-10 1993-05-04 E. R. Squibb & Sons, Inc. Substituted imidazole phosphonic and phosphinic acid derivatives
US5208235A (en) 1992-03-10 1993-05-04 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole derivatives
US5264437A (en) 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
US5602173A (en) 1992-04-02 1997-02-11 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5605923A (en) 1992-04-02 1997-02-25 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
EP0633771A4 (en) 1992-04-02 1995-02-22 Smithkline Beecham Corporation Compounds.
CA2133439C (en) 1992-04-02 2005-07-26 Siegfried Benjamin Christensen, Iv Compounds useful for treating allergic and inflammatory diseases
US5552397A (en) 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
US5212195A (en) 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
AU669364B2 (en) 1992-05-15 1996-06-06 Merrell Pharmaceuticals Inc. Novel mercaptoacetylamido pyridazo(1,2)pyridazine, pyrazolo(1,2)pyridazine, pyridazo(1,2-a)(1,2)diazepine and pyrazolo(1,2-a)(1,2)diazepine derivatives useful as inhibitors of enkephalinase and ace
RU2124503C1 (ru) 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
ES2102036T3 (es) 1992-06-15 1997-07-16 Celltech Therapeutics Ltd Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv.
US5210204A (en) 1992-06-16 1993-05-11 Warner-Lambert Company Biphenyl oxadiazoles and thiadiazoles as angiothesin II antagonists
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
EP0652868B1 (en) 1992-07-28 2004-11-10 Aventis Pharma Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE
US5185340A (en) 1992-08-04 1993-02-09 American Home Products Corporation Pyrimidinyl arylalkyl ethers with antihypertensive activity
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
ES2132254T3 (es) 1992-09-14 1999-08-16 Forssmann Wolf Georg Prof Dr Nueva utilizacion de inhibidores de la fosfodiesterasa iv.
JP3756512B2 (ja) 1992-09-21 2006-03-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 徐放性タンパク質製剤
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5349056A (en) 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
US5504080A (en) 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
WO1994012461A1 (en) 1992-12-02 1994-06-09 Pfizer Inc. Catechol diethers as selective pdeiv inhibitors
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
TW263495B (es) 1992-12-23 1995-11-21 Celltech Ltd
JP3339730B2 (ja) 1992-12-24 2002-10-28 忠弘 大見 半導体装置
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
EP0678018B1 (en) 1993-01-06 2003-04-09 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5358502A (en) 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
US5292736A (en) 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
CA2157793C (en) 1993-03-09 1999-07-13 James E. Woiszwillo Macromolecular microparticles and methods of production
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
US5459151A (en) 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
GB9309324D0 (en) 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
GB9311282D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd New compositions of matter
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
JPH0710875A (ja) 1993-06-21 1995-01-13 Green Cross Corp:The 選択的ホスホジエステラーゼｉｖ阻害剤
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
CN1046939C (zh) 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
HUT74170A (en) 1993-07-06 1996-11-28 Pfizer Bicyclic tetrahydro pyrazolopyridines
US5362727A (en) 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
WO1995004045A1 (en) 1993-07-28 1995-02-09 Rhone-Poulenc Rorer Limited Compounds as pde iv and tnf inhibitors
US6300372B1 (en) 1993-07-30 2001-10-09 Smithkline Beecham Corporation 3-Cyano-3-(3,4-disubstituted) phenylcyclohexyl-1-carboxylates
EP0714397A1 (en) 1993-08-19 1996-06-05 Smithkline Beecham Corporation Phenethylamine compounds
US5665754A (en) 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
AU7957794A (en) 1993-10-01 1995-05-01 Smithkline Beecham Corporation Anti-allergic, anti-inflammatory compounds, compositions and uses
WO1995009624A1 (en) 1993-10-01 1995-04-13 Smithkline Beecham Corporation Compounds, compositions and treatment of allergies and inflammation
WO1995009836A1 (en) 1993-10-01 1995-04-13 Smithkline Beecham Corporation Cyanocyclohexane compounds, compositions, and uses thereof
US5780667A (en) 1993-10-01 1998-07-14 Smithkline Beecham Corporation Compounds, compositions and treatment of allergies and inflammation therewith
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
ATE259648T1 (de) 1993-10-26 2004-03-15 Univ Jefferson Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung
US5489670A (en) 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
GB9322828D0 (en) 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
US5840860A (en) 1993-11-17 1998-11-24 Commonwealth Scientific And Industrial Research Organization Fatty acid delivery system comprising a hydrolyzable bond
US5525723A (en) 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
JP2818820B2 (ja) 1993-11-26 1998-10-30 ファイザー・インク． 抗炎症剤としての３−アリール−２−イソオキサゾリン類
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
PL314605A1 (en) 1993-11-26 1996-09-16 Pfizer Isoxazolin compounds as anti-inflammatory agents
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
ATE260911T1 (de) 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326600D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
MX9603414A (es) 1994-02-17 1997-03-29 American Home Prod Derivados de bifenilo sustituidos como inhibidores de fosfodiesterasa.
CA2143143A1 (en) 1994-03-08 1995-09-09 Toshihiko Tanaka 3-phenylpyrrolidine derivatives
GB9404706D0 (en) 1994-03-11 1994-04-27 Smithkline Beecham Corp Compounds
US5952314A (en) 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
WO1995027692A1 (en) 1994-04-08 1995-10-19 Smithkline Beecham Corporation Subtituted biphenyl tnf inhibitors
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
CA2188269A1 (en) 1994-04-21 1995-11-02 Schering Aktiengesellschaft Pde iv inhibitors for treating multiple sclerosis
ATE357221T1 (de) 1994-04-22 2007-04-15 Astellas Pharma Inc Kolon-spezifisches arzneistofffreisetzungssystem
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
GB9410877D0 (en) 1994-05-31 1994-07-20 Bayer Ag Heterocyclycarbonyl substituted benzoduranyl-and-thiophenyl-alkanecarboxyclic acid derivatives
HRP950288A2 (en) 1994-05-31 1997-08-31 Bayer Ag Oxalylamino-benzofuran- and benzothienyl-derivatives
DK0685475T3 (da) 1994-05-31 1999-08-30 Bayer Ag Amino-benzofuryl- og thienylderivater
GB9412383D0 (en) 1994-06-21 1994-08-10 Celltech Ltd Chemical compound
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
DE69526790T2 (de) 1994-06-24 2003-03-06 Euroceltique S.A., Luxemburg/Luxembourg Verbindungen zur hemmung von phosphodiesrerase iv
US5466697A (en) 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
EP0772610B9 (de) 1994-07-22 2001-07-25 Byk Gulden Lomberg Chemische Fabrik GmbH Dihydrobenzofurane
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
EP0785927B1 (en) 1994-10-12 2003-08-27 Euroceltique S.A. Novel benzoxazoles
BR9509610A (pt) 1994-11-07 1997-10-28 Pfizer Ligandos específicos de neuropeptideo Y1
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5843866A (en) 1994-12-30 1998-12-01 Hampshire Chemical Corp. Pesticidal compositions comprising solutions of polyurea and/or polyurethane
DE19501481A1 (de) 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
AU4766096A (en) 1995-01-31 1996-08-21 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
WO1996023517A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5831115A (en) 1995-04-21 1998-11-03 Abbott Laboratories Inhibitors of squalene synthase and protein farnesyltransferase
US20020006964A1 (en) 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DK0835126T3 (da) 1995-06-27 2003-07-14 Elan Pharm Inc Sammensætninger og formuleringer til fremstilling af analgesimidler og til hamning af fremadskridende neuropatiske amertelidelser
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
AU7074496A (en) 1995-09-18 1997-04-09 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
AUPN634595A0 (en) 1995-11-03 1995-11-30 Borody, Thomas Julius Improved method for colonic evacuation
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
ATE289994T1 (de) 1995-11-24 2005-03-15 Glaxosmithkline Spa Chinolin-derivate
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
AU7692696A (en) 1995-12-01 1997-06-27 Novartis Ag Heteroaryl derivatives
AU7692896A (en) 1995-12-01 1997-06-27 Novartis Ag Quinazolin-2,4-diazirines as NPY receptor antagonist
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
AU7626496A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Heteroaryl compounds
US6236946B1 (en) 1995-12-13 2001-05-22 Thomas S. Scanlan Nuclear receptor ligands and ligand binding domains
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
ATE236137T1 (de) 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
CA2245524A1 (en) 1996-02-02 1997-08-07 Wei Han Antidiabetic agents
CA2244831A1 (en) 1996-02-02 1997-08-07 John T. Olson Method of treating diabetes and related disease states
AU1618697A (en) 1996-02-06 1997-08-28 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
EP0895517B1 (en) 1996-04-23 2004-11-17 Ipsen Manufacturing Ireland Limited Acidic polylactic polymers
WO1997046556A1 (en) 1996-06-07 1997-12-11 Merck & Co., Inc. OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
WO1998005331A2 (en) 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
US5861398A (en) 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
WO1998009537A1 (en) 1996-09-09 1998-03-12 Kiwitech Limited Acid casein or a non-toxic soluble salt thereof and high-methoxyl pectin polymer
AU4176997A (en) 1996-09-16 1998-04-02 Warner-Lambert Company 3-alkyl-3-phenyl-piperidines
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
CA2274594C (en) 1996-12-16 2006-10-10 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
JP2001508799A (ja) 1997-01-21 2001-07-03 スミスクライン・ビーチャム・コーポレイション 新規カンナビノイド受容体モジュレータ
EP0968209A1 (en) 1997-01-28 2000-01-05 Merck & Co., Inc. THIAZOLE BENZENESULFONAMIDES AS $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
KR100510794B1 (ko) 1997-02-04 2005-08-31 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 살진균 카르복스아미드
US6589750B2 (en) 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
HU228509B1 (en) 1997-02-21 2013-03-28 Bayer Ip Gmbh Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
CA2283797A1 (en) 1997-03-18 1998-09-24 Paul Elliot Bender Novel cannabinoid receptor agonists
JPH10324642A (ja) 1997-03-26 1998-12-08 Meiji Seika Kaisha Ltd 大腸送達性構造体
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761265B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
WO1998047505A1 (en) 1997-04-23 1998-10-29 Banyu Pharmaceutical Co., Ltd. Neuropeptide y receptor antagonist
AU735760B2 (en) 1997-04-24 2001-07-12 Merck Sharp & Dohme Limited Use of a NK-1 receptor antagonist and an SSRI for treating obesity
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
SE9702457D0 (sv) 1997-06-26 1997-06-26 Pharmacia & Upjohn Ab Screening
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
AU8127998A (en) 1997-07-11 1999-02-08 Japan Tobacco Inc. Quinoline compounds and medicinal uses thereof
ES2222613T3 (es) 1997-09-12 2005-02-01 Pharis Biotec Gmbh Composicion para la terapia de diabetes mellitus y de la obesidad.
DE19744027A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
US6203513B1 (en) 1997-11-20 2001-03-20 Optonol Ltd. Flow regulating implant, method of manufacture, and delivery device
AU1887999A (en) 1998-01-29 1999-08-16 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
EP1520582A3 (en) 1998-02-02 2009-07-01 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
JP2002506075A (ja) 1998-03-09 2002-02-26 フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ セリンペプチダーゼ調節剤
EP1068207A1 (en) 1998-04-02 2001-01-17 Neurogen Corporation AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
DK1076644T3 (da) 1998-04-29 2004-08-30 Ortho Mcneil Pharm Inc N-Substituerede aminotetraliner som ligander for neutopeptid Y Y5-receptoren, der er nyttig til behandling af fedme og andre lidelser
HRP20000767A2 (en) 1998-05-12 2001-10-31 American Home Prod Benzothiophenes, benzofurans and indoles useful in the treatment of insulin resistance and hyperglycemia
ATE229015T1 (de) 1998-05-12 2002-12-15 Wyeth Corp Zur behandlung von insulin-resistenz und hyperglycemie geeignete biphenyl-oxo-essigsäuren
CA2330555A1 (en) 1998-05-12 1999-11-18 Jay Edward Wrobel Naphtho[2,3-b]heteroar-4-yl derivatives
CA2330623A1 (en) 1998-05-12 1999-11-18 Zenan Li 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia
NZ504106A (en) 1998-05-27 2003-02-28 Dr Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
EP1085869A4 (en) 1998-06-11 2001-10-04 Merck & Co Inc Spiropiperidine derivatives as melanocortin receptor agonists
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19830375A1 (de) 1998-07-08 2000-01-13 K D Pharma Bexbach Gmbh Mikroverkapselte ungesättigte Fettsäure oder Fettsäureverbindung oder Mischung aus Fettsäuren und/oder Fettsäureverbindungen
HN1998000027A (es) 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
DE19837627A1 (de) 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
JP2002525067A (ja) 1998-09-10 2002-08-13 ミレニアム ファーマシューティカルズ インク． レプチン誘導遺伝子
US6337332B1 (en) 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
DE19844547C2 (de) 1998-09-29 2002-11-07 Aventis Pharma Gmbh Polycyclische Dihydrothiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US7417038B1 (en) 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
WO2000023415A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
ATE314371T1 (de) 1998-11-10 2006-01-15 Merck & Co Inc Spiro-indole als y5-rezeptor antagonisten
US6235782B1 (en) 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
IT1304152B1 (it) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
ES2161594B1 (es) 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DE19903087A1 (de) 1999-01-27 2000-08-10 Forssmann Wolf Georg Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
US6344481B1 (en) 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
CA2367666C (en) 1999-03-19 2008-11-25 Carl M. Mendel Method of treating eating disorders
HRP20010700B1 (hr) 1999-03-31 2011-01-31 Janssen Pharmaceutica N.V. Prezelatinizirani skrob u formulaciji s kontroliranim otpustanjem
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
FR2792314B1 (fr) 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PT1183245E (pt) 1999-04-22 2007-07-12 Lundbeck & Co As H Antagonistas selectivos de npy (y5)
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
AU4659200A (en) 1999-05-05 2000-11-21 Ortho-Mcneil Pharmaceutical, Inc. 3a,4,5,9b-tetrahydro-1h-benz(e)indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders
AU778393B2 (en) 1999-05-12 2004-12-02 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
GB9913782D0 (en) 1999-06-14 1999-08-11 Smithkline Beecham Plc Novel compounds
MXPA01012914A (es) 1999-06-15 2004-04-21 Bristol Myers Squibb Co Gama-carbolinas fundidas de heterociclo substituido.
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
WO2001001964A2 (en) 1999-06-23 2001-01-11 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
ES2315753T3 (es) 1999-06-23 2009-04-01 Institut Pasteur Composiciones para el tratamiento de problemas de relaciones interpersonales y trastornos del comportamiento.
DE60023141T2 (de) 1999-06-30 2006-06-14 Lundbeck As Valby H Selektive npy (y5) antagonisten
CN1171872C (zh) 1999-06-30 2004-10-20 图拉列克股份有限公司 调节PPARγ活性的化合物
AU6000900A (en) 1999-07-23 2001-02-13 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
MXPA02000927A (es) 1999-07-28 2003-07-14 Johnson & Johnson Amina y derivados de amida como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de obesidad y otros trastornos.
DE60027334T2 (de) 1999-08-18 2007-03-29 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Zusammensetzung mit verzögerter Abgabe in der ein Peptid mit einem Polymer komplexiert ist
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
EP1206262A4 (en) 1999-08-26 2003-01-02 Bristol Myers Squibb Co Y NEUROPEPTID ANTAGONISTS: SPIROISOQUINOLINONE DERIVATIVES
EP1227134B1 (en) 1999-08-31 2006-10-04 Daikin Industries, Ltd. Polymer composition crosslinkable with ultraviolet
SE9903291D0 (sv) 1999-09-15 1999-09-15 Astra Ab New process
AU7315800A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Mch antagonists
ES2258476T3 (es) 1999-09-30 2006-09-01 Neurogen Corporation Ciertos heterociclos sustituidos con alquilendiaminas.
EP1218381B1 (en) 1999-09-30 2006-12-06 Neurogen Corporation AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES
JP2003510325A (ja) 1999-09-30 2003-03-18 ニューロジェン・コーポレーション ある種のアルキレンジアミン−置換ピラゾロ［１，５−ａ］−１，５−ピリミジン及びピラゾロ［１，５−ａ］−１，３，５−トリアジン
EP1220872A1 (en) 1999-10-06 2002-07-10 Pharmacia Corporation Uroguanylin as an intestinal cancer inhibiting agent
AU7802700A (en) 1999-10-06 2001-05-10 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
WO2001027068A1 (en) 1999-10-13 2001-04-19 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
DE19949319A1 (de) 1999-10-13 2001-06-13 Ruetgers Vft Ag Verfahren zur Herstellung von Arylalkylethern
WO2001032180A2 (en) 1999-11-01 2001-05-10 Rodeva Limited Composition for treatment of constipation and irritable bowel syndrome
CA2389703A1 (en) 1999-11-05 2001-05-10 Aventis Pharma Deutschland Gmbh Indeno-, naphtho-, and benzocyclohepta-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments
AR032292A1 (es) 1999-12-16 2003-11-05 Schering Corp Imidazoles sustituidos, composiciones farmaceuticas y el uso de dichos imidazoles para la manufactura de un medicamento para los tratamientos de desordenes en la alimentacion
FR2802817B1 (fr) 1999-12-23 2002-10-11 Centre Nat Rech Scient Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
CA2396037A1 (en) 1999-12-31 2001-07-12 Rutgers, The State University Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
US7521061B2 (en) 1999-12-31 2009-04-21 Rutgers, The State University Of New Jersey Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
JP4917726B2 (ja) 1999-12-31 2012-04-18 ルトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー ポリマー混合物および活性化合物からなる徐放用医薬製剤
US20030064105A1 (en) 2000-08-25 2003-04-03 Myung-Jin Kim Lipophilic-coated microparticle containing a protein drug and formulation comprising same
AU2001229491A1 (en) 2000-01-18 2001-07-31 Merck And Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
WO2001054698A1 (en) 2000-01-26 2001-08-02 Warner-Lambert Company Method for preventing or treating postoperative ileus
AU2001228325A1 (en) 2000-02-01 2001-08-14 Novo-Nordisk A/S Use of compounds for the regulation of food intake
US6653304B2 (en) 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
AU2001234128B2 (en) 2000-02-22 2004-11-11 Banyu Pharmaceutical Co., Ltd. Novel imidazoline compounds
GB0004003D0 (en) 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
NZ520926A (en) 2000-02-23 2004-08-27 Aventis Pharma Gmbh 8,8a-dihydro-indeno[1,2-d]thiazole derivatives, substituted in position 8a, a method for their production and their use as medicaments, e.g. anorectic agents
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
SK285571B6 (sk) 2000-02-26 2007-04-05 Sanofi-Aventis Deutschland Gmbh 8,8a-Dihydroindeno[1,2-d]tiazolové deriváty nesúce v polohe 2 substituent so sulfónamidovou štruktúrou, spôsob ich prípravy a farmaceutické prostriedky, ktoré ich obsahujú
WO2001064212A1 (en) 2000-03-01 2001-09-07 University College London Modulators of the endocannabinoid uptake and of the vallinoid receptors
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
AU2001260113B2 (en) 2000-03-14 2006-04-06 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
CA2403631A1 (en) 2000-03-23 2001-09-27 Brenda L. Palucki Spiropiperidine derivatives as melanocortin receptor agonists
UA74367C2 (uk) 2000-03-23 2005-12-15 Сольве Фармас'Ютікалз Б.В. ПОХІДНІ 4,5-ДИГІДРО-1Н-ПІРАЗОЛУ, ЩО ВИЯВЛЯЮТЬ АНТАГОНІСТИЧНУ АКТИВНІСТЬ ЩОДО СВ<sub>1</sub>, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЇЇ ВИГОТОВЛЕННЯ, СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ (ВАРІАНТИ)
JP2003528088A (ja) 2000-03-23 2003-09-24 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬としての置換ピペリジン類
PH12001000675B1 (en) 2000-04-04 2009-09-22 Australian Food Ind Sci Ct Encapsulation of food ingredients
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
EP1142886A1 (en) 2000-04-07 2001-10-10 Aventis Pharma Deutschland GmbH Percyquinnin, a process for its production and its use as a pharmaceutical
DE60119715T3 (de) 2000-04-10 2016-12-08 Nicholas John Wald Zusammensetzung zur prävention kardiovaskulärer erkrankungen
AU2001248279A1 (en) 2000-04-17 2001-10-30 Novo-Nordisk A/S New compounds, their preparation and use
WO2001078781A2 (en) 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
CA2407149C (en) 2000-04-28 2010-10-12 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0011013D0 (en) 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
US6432960B2 (en) 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
WO2001085173A1 (en) 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Alkylamine derivatives of dihydropyridine npy antagonists
US6444675B2 (en) 2000-05-10 2002-09-03 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
CA2408486A1 (en) 2000-05-11 2001-11-15 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
AU2001259056A1 (en) 2000-05-17 2001-11-26 Eli Lilly And Company Method for selectively inhibiting ghrelin action
US6391881B2 (en) 2000-05-19 2002-05-21 Bristol-Myers Squibb Company Thiourea derivatives of dihydropyridine NPY antagonists
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
CA2410597A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
US6645987B2 (en) 2000-06-15 2003-11-11 Schering Corporation Nor-seco himbacine derivatives useful as thrombin receptor antagonists
ES2238458T3 (es) 2000-06-16 2005-09-01 Smithkline Beecham Plc Piperidinas para uso como antagonistas de los receptores de orexina.
EP1299362A4 (en) 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
MXPA03000174A (es) 2000-07-06 2003-09-22 Neurogen Corp Ligandos de receptor de hormona concentradora de melanina.
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
IL152528A0 (en) 2000-07-13 2003-05-29 Lilly Co Eli Beta3 adrenergic agonists
CN1443198A (zh) 2000-07-24 2003-09-17 阿达纳生物科学有限公司 Ghrelin拮抗剂
CN1277828C (zh) 2000-07-31 2006-10-04 霍夫曼-拉罗奇有限公司 哌嗪衍生物
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
AU2001288294A1 (en) 2000-08-21 2002-03-04 Merck And Co., Inc. Anti-hypercholesterolemic drug combination
WO2002015905A1 (en) 2000-08-21 2002-02-28 Gliatech, Inc. The use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
WO2005032474A2 (en) 2003-09-30 2005-04-14 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US20020037829A1 (en) 2000-08-23 2002-03-28 Aronson Peter S. Use of DPPIV inhibitors as diuretic and anti-hypertensive agents
EP1320366A4 (en) 2000-08-23 2005-04-06 Merck & Co Inc SUBSTITUTED PIPERIDINES AS MELANOCORTIN RECEPTOR AGONISTS
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
JP2004509108A (ja) 2000-09-14 2004-03-25 シェーリング　コーポレイション 置換尿素神経ペプチドｙｙ５受容体アンタゴニスト
AU2001292518A1 (en) 2000-09-26 2002-04-08 Biovitrum Ab Novel compounds
AU2001292480A1 (en) 2000-09-26 2002-04-08 Biovitrum Ab Novel pyridazine compounds for the treatment of diabetes
JP2002114768A (ja) 2000-10-11 2002-04-16 Japan Tobacco Inc ２−（２，５−ジハロゲン−３，４−ジヒドロキシフェニル）アゾール化合物及びそれを含有してなる医薬組成物
BR0114630A (pt) 2000-10-13 2003-07-01 Lilly Co Eli Secretagogos de hormÈnio do crescimento
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
WO2002044152A1 (en) 2000-10-16 2002-06-06 F. Hoffmann-La Roche Ag Indoline derivatives and their use as 5-ht2 receptor ligands
CN1469876A (zh) 2000-10-20 2004-01-21 �Ʒ� α-芳基乙醇胺及其用作β-3肾上腺素能受体激动剂的用途
AU2002227170A1 (en) 2000-11-03 2002-05-15 Wyeth Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives
JP2004532609A (ja) 2000-11-03 2004-10-28 ザ リージェント オブ ザ ユニバーシティ オブ カリフォルニア プロキネチシンポリペプチド、関連組成物および方法
DE10055857A1 (de) 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
IL154928A0 (en) 2000-11-10 2003-10-31 Lilly Co Eli 3-substituted oxindole beta 3 agonists
EP1337518B1 (en) 2000-11-20 2009-06-17 Biovitrum AB (publ) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
IL155702A0 (en) 2000-11-20 2003-11-23 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
AU2002224885A1 (en) 2000-11-28 2002-06-11 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US6566367B2 (en) 2000-12-12 2003-05-20 Pfizer Inc. Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
CA2431800C (en) 2000-12-14 2014-07-08 Amylin Pharmaceuticals, Inc. Peptide yy and peptide yy agonists for treatment of metabolic disorders
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
ES2316486T3 (es) 2000-12-21 2009-04-16 Schering Corporation Antagonsitas de los receptores y5 del neuropeptido y heteroaril-urea.
PT1216707E (pt) 2000-12-22 2005-06-30 Pasteur Institut Novas utilizacoes terapeuticas para um smr-1-peptideo
JP2004520324A (ja) 2000-12-22 2004-07-08 アストラゼネカ アクチボラグ カルバゾール誘導体およびニューロペプチドｙ５受容体リガンドとしてのそれらの使用
US6472394B1 (en) 2000-12-22 2002-10-29 Schering Corporation MCH antagonists and their use in the treatment of obesity
JP4088412B2 (ja) 2000-12-26 2008-05-21 トヨタ自動車株式会社 内燃機関の空燃比制御装置
CN1250549C (zh) 2000-12-27 2006-04-12 霍夫曼-拉罗奇有限公司 吲哚衍生物及其作为5－ht2b和5－ht2c受体配体的应用
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
EP1368339A1 (en) 2001-01-23 2003-12-10 Eli Lilly &amp; Company Substituted piperidines/piperazines as melanocortin receptor agonists
JP2004524297A (ja) 2001-01-23 2004-08-12 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニスト
CA2432985A1 (en) 2001-01-23 2002-08-01 Vincent Mancuso Piperazine- and piperidine-derivatives as melanocortin receptor agonists
CA2435415A1 (en) 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticles of biodegradable polymer encapsulating a biologically active substance
DK1385548T3 (da) 2001-01-26 2007-09-10 Schering Corp Kombinationer af sterolabsorptionsinhibitor(er) med (et eller flere) kardiovaskulære midler til behandling af vaskulære tilstande
JP2004527476A (ja) 2001-02-02 2004-09-09 ファイザー・インク 真性糖尿病の処置
KR20030074774A (ko) 2001-02-02 2003-09-19 다케다 야쿠힌 고교 가부시키가이샤 접합 헤테로시클릭 화합물
AU2002235520A1 (en) 2001-02-02 2002-08-19 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
CA2436741A1 (en) 2001-02-05 2002-08-15 Dr. Reddy's Laboratories Limited Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents
AU2002250343B2 (en) 2001-02-28 2006-05-25 Merck Sharp & Dohme Corp. Acylated piperidine derivatives as melanocortin-4 receptor agonists
ES2262798T3 (es) 2001-02-28 2006-12-01 Smithkline Beecham Corporation Derivados glicolicos de xantinas para tratar el sindrome del intestino irritable.
JP4104983B2 (ja) 2001-02-28 2008-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体
DE60215132T2 (de) 2001-02-28 2007-08-23 Merck & Co., Inc. Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
GB0105772D0 (en) 2001-03-08 2001-04-25 Sterix Ltd Use
WO2002072033A2 (en) 2001-03-13 2002-09-19 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms containing glucocorticosteroid
EP1367968A4 (en) * 2001-03-16 2006-12-13 Glaukos Corp APPLICATOR AND METHOD FOR SETTING A TRABECULAR SHUNT FOR GLUCKOM TREATMENT
EP1383376A4 (en) 2001-03-19 2006-03-08 Praecis Pharm Inc PHARMACEUTICAL FORMULATIONS WITH PROLONGED RELEASE
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
EP1370520A1 (en) 2001-03-21 2003-12-17 Pharmacopeia, Inc. Aryl and biaryl compounds having mch modulatory activity
ATE284872T1 (de) 2001-03-22 2005-01-15 Solvay Pharm Bv 4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer wirkung
WO2001074782A1 (en) 2001-03-29 2001-10-11 Molecular Design International, Inc. β3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
DE60233040D1 (de) 2001-03-29 2009-09-03 Synergy Pharmaceuticals Inc Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese
GB0108631D0 (en) 2001-04-05 2001-05-30 Melacure Therapeutics Ab Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
US7431710B2 (en) * 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
JP4280073B2 (ja) 2001-04-12 2009-06-17 ファーマコペイア ドラッグ ディスカバリー， インコーポレイテッド Ｍｃｈアンタゴニストとして使用されるアリールピペリジンおよびビアリールピペリジン
DK2322631T3 (en) 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
CA2446514A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
MXPA03010129A (es) 2001-05-05 2004-03-10 Smithkline Beecham Plc N-aroilaminas-ciclicas.
EP1435955A2 (en) 2001-05-05 2004-07-14 SmithKline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
KR20040018260A (ko) 2001-05-21 2004-03-02 뉴로크린 바이오사이언시즈 인코퍼레이티드 Ｃｒｆ 수용체 길항제로서의 트리- 및테트라아자-아세나프틸렌 유도체
AU2002338896B2 (en) 2001-05-21 2006-04-27 F.Hoffman-La Roche Ag Quinoline derivatives as ligands for the neuropeptide Y receptor
JP2005515961A (ja) 2001-05-22 2005-06-02 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド：置換１−ベンジル−４−アリールピペラジン類似体
DE10292434D2 (de) 2001-06-05 2004-07-29 Yueksel Savas Verwendung eines Peptids, welches Guanylat Cyclase C aktiviert, für die Behandlung von Atemwegserkrankungen über die Luftwege, Arzneimittel, Inhalationsvorrichtung und Diagnoseverfahren
CA2450475A1 (en) 2001-06-20 2003-01-03 Linda Brockunier Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2003000685A1 (fr) 2001-06-20 2003-01-03 Takeda Chemical Industries, Ltd. Derives heterocycliques a 5 chainons
JP2004535433A (ja) 2001-06-20 2004-11-25 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療用のジペプチジルペプチダーゼ阻害薬
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
CN1688599A (zh) 2001-06-27 2005-10-26 前体生物药物股份有限公司 二肽基肽酶iv抑制剂的新用途
DE60221983T2 (de) 2001-06-27 2008-05-15 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
CN1990469A (zh) 2001-06-27 2007-07-04 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
ES2296962T3 (es) 2001-06-27 2008-05-01 Smithkline Beecham Corporation Pirrolidinas como inhibidores de dipeptidil peptidasa.
JP2003018009A (ja) 2001-06-29 2003-01-17 Mitsubishi Electric Corp デジタルアナログコンバータ
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
EP1404675B1 (en) 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
JP2004536104A (ja) 2001-07-05 2004-12-02 シナプティック・ファーマスーティカル・コーポレーション Ｍｃｈ選択的アンタゴニストとしての置換されたアニリン−ピペリジン誘導体
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
EP1409521A2 (en) 2001-07-12 2004-04-21 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
ATE411021T1 (de) 2001-07-18 2008-10-15 Merck & Co Inc Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten
US20030017195A1 (en) 2001-07-20 2003-01-23 Samir Mitragotri Method for oral drug delivery
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
CA2454830C (en) 2001-07-26 2010-02-02 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
WO2003011267A1 (fr) 2001-07-31 2003-02-13 The Nisshin Oillio, Ltd. Medicaments anti-obesite et ses substances
GB0119172D0 (en) 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
WO2003014113A1 (en) 2001-08-06 2003-02-20 Glenmark Pharmaceuticals Limited Novel benzopyran compounds and process for their preparation and use
MXPA04001144A (es) 2001-08-07 2004-07-08 Banyu Pharma Co Ltd Compuestos espiro.
CA2456964A1 (en) 2001-08-08 2003-02-20 Merck & Co., Inc. Melanin-concentrating hormone antagonists
EP1444224B1 (en) 2001-08-14 2006-05-03 Eli Lilly And Company 3-substituted oxindole beta-3 agonists
WO2003016307A1 (en) 2001-08-14 2003-02-27 Eli Lilly And Company β3 ADRENERGIC AGONISTS
DE10139416A1 (de) 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
US20040198774A1 (en) 2001-08-23 2004-10-07 Shinichi Ishii Preventive and/or remedial agent for disease attributable to arteriosclerotic activity
US20030092041A1 (en) 2001-08-23 2003-05-15 Millennium Pharmaceuticals, Inc. Novel use for muscarinic receptor M5 in the diagnosis and treatment of metabolic disorders
EP1421077A4 (en) 2001-08-31 2004-11-17 Univ Connecticut NEW PYRAZOLANALOGS ON CANNABINOID RECEPTORS
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
US6915444B2 (en) 2001-09-12 2005-07-05 Rockwell Automation Technologies, Inc. Network independent safety protocol for industrial controller using data manipulation techniques
EP1426370A4 (en) 2001-09-13 2009-12-23 Nisshin Pharma Inc PROPANOLAMINE DERIVATIVE WITH 1,4-BENZODIOXANRING
EP1426366A4 (en) 2001-09-14 2004-12-08 Mitsubishi Pharma Corp THIAZOLIDE DERIVATIVES AND THEIR MEDICAL USE
EP1434765B1 (en) 2001-09-14 2009-12-02 High Point Pharmaceuticals, LLC Substituted piperidines with selective binding to histamine h3-receptor
CA2459454A1 (en) 2001-09-14 2003-03-27 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
WO2003024928A2 (en) 2001-09-14 2003-03-27 Novo Nordisk A/S Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
AU2002331311A1 (en) 2001-09-19 2003-04-01 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
AU2002333852B2 (en) 2001-09-21 2006-07-13 Solvay Pharmaceuticals B.V. Novel 4,5-dihydro-1H-pyrazole derivativeshaving CB1-antagonistic activity
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CN1529595A (zh) 2001-09-21 2004-09-15 ������ҩ�����޹�˾ 具有效cb1-拮抗活性的4,5-2氢-1h-吡唑衍生物
US6509367B1 (en) 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
JP2005532982A (ja) 2001-09-24 2005-11-04 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのピロール誘導体の製造及び使用
JP2005514008A (ja) 2001-09-24 2005-05-19 オレゴン ヘルス アンド サイエンス ユニバーシティー 摂食行動を改変する薬剤をスクリーニングするための、弓状核におけるニューロンの評価方法
UY27450A1 (es) 2001-09-24 2003-04-30 Bayer Corp Preparación y uso de derivados de imidazol para el tratamiento de la obesidad
WO2003026576A2 (en) 2001-09-24 2003-04-03 Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College Induction of brown adipocytes by transcription factor nfe2l2
BR0212985A (pt) 2001-09-24 2005-08-30 Imp College Innovations Ltd Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
JP2005504100A (ja) 2001-09-24 2005-02-10 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の治療のための１，５，６，７−テトラヒドロピロロ［３，２−ｃ］ピリジン誘導体の製造法および使用
US20040191926A1 (en) 2001-09-26 2004-09-30 Zhong-Yin Zhang Ptp1b inhibitors and ligands
KR20040041177A (ko) 2001-09-26 2004-05-14 바이엘 파마슈티칼스 코포레이션 당뇨병 치료제로서의 1,6-나프티리딘 유도체
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
US7544690B2 (en) 2001-10-01 2009-06-09 Taisho Pharmaceutical Co., Ltd. MCH receptor antagonists
WO2003029210A2 (en) 2001-10-04 2003-04-10 Merck & Co. Inc. Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
WO2003031439A1 (en) 2001-10-05 2003-04-17 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole
WO2003031410A1 (en) 2001-10-09 2003-04-17 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
FR2830451B1 (fr) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
CA2461369A1 (en) 2001-10-09 2003-04-17 Pharmacia & Upjohn Company Arylsulphonyl-substituted tetrahydro-and-hexahydro-carbazoles as 5-ht-6 receptor ligands
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
ES2256560T3 (es) 2001-10-12 2006-07-16 Bayer Pharmaceuticals Corporation Heterociclos de 5 mienbros que contienen nitrogeno sustituidos con felino para el tratamiento de la obesidad.
US6573396B2 (en) 2001-10-12 2003-06-03 Exxonmobil Chemical Patents Inc. Co-production of dialkyl carbonates and diols with treatment of hydroxy alkyl carbonate
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
EP1446110A2 (en) 2001-10-16 2004-08-18 Structural Bioinformatics Inc. Organosulfur inhibitors of tyrosine phosphatases
PL369732A1 (en) 2001-10-16 2005-05-02 Dr.Reddy's Laboratories Ltd. Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them
HUP0401837A2 (hu) 2001-10-17 2004-12-28 Novo Nordisk A/S Dikarbonsavszármazékok, előállításuk és gyógyászati alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
US7022730B2 (en) 2001-10-19 2006-04-04 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
WO2003035061A1 (en) 2001-10-23 2003-05-01 Biovitrum Ab Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake
HUP0700124A2 (en) 2001-10-25 2007-06-28 Takeda Chemical Industries Ltd Quinoline compound
WO2003035602A1 (en) 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
SE0103648D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
SE0103644D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
EP1450806B1 (en) 2001-11-09 2009-04-29 Biovitrum AB (publ) Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
US7087601B2 (en) 2001-11-30 2006-08-08 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
HUP0402486A3 (en) 2001-11-30 2007-05-02 Lilly Co Eli Nitrogen containing heterocyclic compounds as peroxisome proliferator activated receptor agonists, their use and pharmaceutical compositions cointaining them
ES2269822T3 (es) 2001-12-04 2007-04-01 F. Hoffmann-La Roche Ag Derivados de pirazol de anillos fusionados.
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
DE10160409A1 (de) 2001-12-10 2003-06-18 Guenther Beisel Verwendung von ionischen und nichtionischen Celluloseethern zur Herstellung eines gelartigen Mittels zur Verhinderung der Resorption von Fetten aus dem Magen-Darm-Trakt
US6923992B2 (en) 2001-12-17 2005-08-02 The Chinese University Of Hong Kong Active compounds of Bao-Ji-Wan for anti-diarrhea and relieving gastrointestinal symptoms
JP4286146B2 (ja) 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤
US7105548B2 (en) 2001-12-18 2006-09-12 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
US20030198619A1 (en) 2001-12-19 2003-10-23 Dong Liang C. Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
EP1458385A4 (en) 2001-12-19 2005-12-21 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR 5-HETEROARYL-SUBSTITUTED IMIDAZOLE MODULATORS
WO2003053976A1 (en) 2001-12-20 2003-07-03 Biovitrum Ab PIPAZOLO [1,5-a] PYRIMIDINE DERIVATIVES AS MODULATORS OF PPAR
FR2833949B1 (fr) 2001-12-21 2005-08-05 Galderma Res & Dev NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS PPARy, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
EP1458710A4 (en) 2001-12-21 2005-04-20 Merck & Co Inc Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
US6642381B2 (en) 2001-12-27 2003-11-04 Hoffman-La Roche Inc. Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
US20030129160A1 (en) 2002-01-09 2003-07-10 John-Olov Jansson Use of Interleukin-6
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
EP1478437B1 (en) 2002-02-27 2005-08-31 Pfizer Products Inc. Acc inhibitors
US7943575B2 (en) 2002-03-04 2011-05-17 Ipsen Pharma S.A.S. Sustained release drug formulations containing a carrier peptide
JP2005526079A (ja) 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
US20030219479A1 (en) 2002-04-08 2003-11-27 Lavipharm Laboratories Inc. Multi-layer mucoadhesive drug delivery device with bursting release layer
FR2838439B1 (fr) 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
SE0201175L (sv) 2002-04-18 2003-10-19 Jonsered Cranes Ab Kranarrangemangstillhörig hållarenhet
CN101310723A (zh) 2002-05-17 2008-11-26 迪欧加药品公司 有效的选择性阿片受体调制剂化合物的用途
GB0214013D0 (en) 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
US6991726B2 (en) 2002-07-01 2006-01-31 Usfilter Corporation Filter having a media retaining plate
DE60325606D1 (de) * 2002-07-19 2009-02-12 Univ Yale Uveosklerale drainagevorrichtung
AU2003270009A1 (en) 2002-08-30 2004-03-19 Biorexis Pharmaceutical Corporation Oral delivery of modified transferrin fusion proteins
AU2003264431A1 (en) 2002-09-18 2004-04-08 Ajinomoto Co., Inc. Composition against stress-related diseases
BR0314584A (pt) 2002-09-20 2005-08-09 Pfizer Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4
EP1556010A4 (en) 2002-10-31 2007-12-05 Supergen Inc PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
BR0316950A (pt) 2002-12-02 2006-01-17 Hoffmann La Roche Derivados de indazol como antagonistas de crf
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20040121994A1 (en) 2002-12-20 2004-06-24 Anderson Steven N. Novel amides that activate soluble guanylate cyclase
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
AR042667A1 (es) 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
WO2004064769A2 (en) 2003-01-21 2004-08-05 Hector Herrera Methods for making and using topical delivery agents
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR101227626B1 (ko) 2003-01-28 2013-02-01 아이언우드 파마슈티컬스, 인코포레이티드 위장병 치료 방법 및 위장병 치료용 조성물
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US6683072B1 (en) 2003-02-04 2004-01-27 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of irritable bowel syndrome and nonulcer dyspepsia
JP2006521810A (ja) 2003-03-11 2006-09-28 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
BRPI0409128A (pt) 2003-04-08 2006-03-28 Progenics Pharm Inc uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
CN100372851C (zh) 2003-05-05 2008-03-05 弗·哈夫曼-拉罗切有限公司 具有crf活性的稠合的嘧啶衍生物
CA2525273C (en) 2003-05-16 2012-04-17 Vela Pharmaceuticals, Inc. Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
US7173010B2 (en) 2003-05-19 2007-02-06 Regents Of The University Of Michigan Orphanin FQ receptor
US7073363B2 (en) 2003-05-20 2006-07-11 Schumag Ag Method for processing drawn material and drawn material production installation
JP2007501866A (ja) 2003-06-13 2007-02-01 マイクロバイア インコーポレイテッド 胃腸疾患の治療のための方法および組成物
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
AU2004249211A1 (en) 2003-06-16 2004-12-29 Andrx Pharmaceuticals, Llc Oral extended-release composition
DE10331723A1 (de) 2003-07-11 2005-06-16 Merck Patent Gmbh Kappa-Agonisten
AP2006003585A0 (en) 2003-09-19 2006-04-30 Penwest Pharmaceuticals Co Delayed release dosage forms.
AU2004275835B2 (en) 2003-09-26 2011-06-23 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
US7002015B2 (en) 2003-10-14 2006-02-21 Bristol-Myers Squibb Company 3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants
US7291125B2 (en) * 2003-11-14 2007-11-06 Transcend Medical, Inc. Ocular pressure regulation
CA2545399C (en) 2003-11-21 2013-01-29 Commonwealth Scientific & Industrial Research Organisation Protein-polysaccharide microcapsules for delivering active agents to the gi tract
US20050136121A1 (en) 2003-12-22 2005-06-23 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
JP2007516297A (ja) 2003-12-23 2007-06-21 アルザ・コーポレーシヨン 制御送達用薬剤組成物の溶解度を高くする方法および投薬形態物
US20050267197A1 (en) 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses
EP1781339B1 (en) 2004-06-25 2013-12-25 Thomas Jefferson University Guanylyl cyclase C ligands
US20060013889A1 (en) 2004-07-16 2006-01-19 Playford Raymond J Colostrum-based treatment for irritable bowel syndrome
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
TW201837984A (zh) 2004-11-18 2018-10-16 日商尼康股份有限公司 曝光裝置、曝光方法、及元件製造方法
US20090253634A1 (en) 2005-08-19 2009-10-08 Microbia, Inc. Methods and Compositions for the Treatment of Gastrointestinal Disorders
US20070101158A1 (en) 2005-10-28 2007-05-03 Elliott Robert C Security region in a non-volatile memory
US20090192083A1 (en) 2006-02-24 2009-07-30 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7692307B2 (en) 2006-12-08 2010-04-06 Intel Corporation Compliant structure for an electronic device, method of manufacturing same, and system containing same
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
MX2009011898A (es) 2007-05-04 2009-11-18 Ironwood Pharmaceuticals Inc Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) * 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2559840T3 (es) 2008-06-04 2016-02-16 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2373296B1 (en) 2008-12-03 2016-08-03 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US8507447B2 (en) 2009-11-09 2013-08-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
RU2012128509A (ru) 2009-12-07 2014-01-20 Айронвуд Фармасьютикалз, Инк. Способы лечения заболеваний желудочно-кишечного тракта
WO2012037380A2 (en) * 2010-09-15 2012-03-22 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (en) * 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN105764916B (zh) * 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法

Also Published As

Publication number Publication date
CN103601792A (zh) 2014-02-26
CN101772513A (zh) 2010-07-07
IL202510A (en) 2017-11-30
US20170209531A1 (en) 2017-07-27
US20110160120A1 (en) 2011-06-30
EP2170930B1 (en) 2012-08-15
ES2393885T3 (es) 2012-12-28
IL254406B (en) 2022-01-01
ES2559319T3 (es) 2016-02-11
JP2016056187A (ja) 2016-04-21
JP5546451B2 (ja) 2014-07-09
US9266926B2 (en) 2016-02-23
US7879802B2 (en) 2011-02-01
AU2008261102A1 (en) 2008-12-11
CN101772513B (zh) 2013-11-13
IL202510A0 (en) 2010-06-30
CA3089569C (en) 2023-12-05
CA2688161A1 (en) 2008-12-11
US20160243188A1 (en) 2016-08-25
US20140024605A1 (en) 2014-01-23
CA2688161C (en) 2020-10-20
US8901075B2 (en) 2014-12-02
WO2008151257A2 (en) 2008-12-11
EP2527360A9 (en) 2013-11-13
US10711038B2 (en) 2020-07-14
US9914752B2 (en) 2018-03-13
WO2008151257A3 (en) 2009-03-05
EA020466B1 (ru) 2014-11-28
EP2998314B1 (en) 2020-01-22
MX381737B (es) 2025-03-13
MX2009013293A (es) 2010-02-15
JP2010530849A (ja) 2010-09-16
US20090048175A1 (en) 2009-02-19
US20200283480A1 (en) 2020-09-10
EP2998314A1 (en) 2016-03-23
EP2170930B3 (en) 2013-10-02
US20160340390A1 (en) 2016-11-24
HK1221958A1 (en) 2017-06-16
CA3089569A1 (en) 2008-12-11
US9238677B2 (en) 2016-01-19
EP2170930A2 (en) 2010-04-07
US20240002440A1 (en) 2024-01-04
US8716224B2 (en) 2014-05-06
JP6412028B2 (ja) 2018-10-24
AU2008261102B2 (en) 2013-11-28
DK2170930T3 (da) 2012-11-05
JP2014185158A (ja) 2014-10-02
EP2527360A3 (en) 2013-02-20
EP2527360A2 (en) 2012-11-28
CN103601792B (zh) 2016-06-29
EP2527360B1 (en) 2015-10-28
US20180273586A1 (en) 2018-09-27
JP6034329B2 (ja) 2016-11-30
EA200971130A1 (ru) 2010-06-30
ES2393885T7 (es) 2014-01-30
HK1142085A1 (en) 2010-11-26
IL254406A (en) 2018-02-28
US20140329738A1 (en) 2014-11-06
US20150057235A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
MX354786B (es) Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
WO2009149278A8 (en) Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A3 (en) Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2810951A3 (en) Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EA201491697A1 (ru) Составы агонистов гуанилатциклазы с и способы применения
EA201171464A1 (ru) Антитела
WO2010065751A3 (en) Formulations of guanylate cyclase c agonists and methods of use
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
BRPI0514474A (pt) multiparticulados
DOP2014000260A (es) Compuestos d-aminoácidos para enfermedad hepática
CY1118847T1 (el) Συνθεση που βελτιωνει την αποδοση και χρηση αυτης
BR112012025517A2 (pt) ____________________________________________________________ anticorpo que reconhece fator inibidor de leucemia (lif) humano e uso de anti-lif anticorpos no tratamento de doenças associadas a proliferação celular não desejada
AR052082A1 (es) Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante el incremento de la concentracion sanguinea de gelp -1
CO6410314A2 (es) Proteínas de unión a il-17
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
CL2011001464A1 (es) Compuestos derivados de purina, agonistas del receptor cb2; composicion farmaceutica que los comprende; y uso del compuesto para tratar el dolor osteoartritico.
AR063493A1 (es) Nuevos anticuerpos anti notch 3 y su uso para la deteccion y el diagnostico de enfermedades
MX2009002787A (es) Composiciones y métodos para prevenir el cáncer con cupredoxinas.
CL2007002494A1 (es) Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion.
BR112013026573A2 (pt) fórmula de lactente para uso na prevenção de doenças cardiovasculares
GT200600145A (es) Combinacion para terapia en hiperplasia benigna de prostata
MX2010000997A (es) Combinaciones farmaceuticas que comprenden un inhibidor de tirosina cinasa y un anticuerpo contra integrina alfa 1 beta 5 (cd49b).
BRPI0608012A2 (pt) método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista
CR9853A (es) Compuestos de exemestano (s)-6-metiloxaalquilo y metodos relacionados con su utilizacion
BR112013011068A2 (pt) &#34;antagonistas de a2a como potenciadores das funções cognitiva e motora&#34;